NMS·Healthcare·$191M·#520 / 520 in Healthcare
HUMA Humacyte, Inc.
7CRITICAL
CATEGORY BREAKDOWN
GROWTH0
QUALITY0
STABILITY6
VALUATION0
GOVERNANCE35
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
N/A
0
> 50% strong
Gross Margin
Revenue retained after direct costs
-376.1%
0
> 50% strong
Cash Runway
Months of cash at current burn rate
6 months
10
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
2085.8%
0
< 25% strong
Price / Sales
Market cap relative to trailing revenue
94.7x
0
< 3x strong
Rule of 40
Growth rate plus operating margin
N/A
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
7.5%
53
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+72.5%
0
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE HUMA WITH…
OR QUICK-COMPARE SECTOR PEERS
RELATED RESEARCH
We Scored 313 Small-Cap Biotechs — 80% Score Below 50. Here's Why That's Correct.May 28, 2026SCORE ALERT
Get notified when HUMA's score changes by 5+ points.
DATA INFO
Last updated: Jul 1, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.